One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

Neurology

Volumn 62, Issue 11, 2004, Pages 2113-2115

  Wick, Wolfgang ^a   Steinbach, J P ^a   Kuker W M ^b   Dichgans, J ^a   Bamberg, M ^b   Weller, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VOMITING;

EID: 2942532908     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000127617.89363.84     Document Type: Article

References (7)

1. Glioma Meta-analysis Trialists Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-1018.
2. MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
3. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
4. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593.
5. Figueroa JA. Protracted cyclic administration of temozolomide is feasible. A phase I pharmacokinetic and pharmacodynamic study. Presented at the 36th Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, LA.
6. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383-1388.
7. Jaeckle KA, Hess KR, Yung WKA, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 2003;21:2305-2311.